Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
Portfolio Pulse from
Trevi Therapeutics announced positive results from a study on the abuse potential of oral nalbuphine, showing lower 'Drug Liking' scores compared to butorphanol. The company will discuss these findings in a conference call and webcast.
December 03, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trevi Therapeutics' study on oral nalbuphine shows lower abuse potential compared to butorphanol, which could enhance the drug's marketability and impact stock positively.
The positive results from the study suggest that oral nalbuphine has a lower abuse potential, which is a significant factor for regulatory approval and market acceptance. This could lead to increased investor confidence and a potential rise in TRVI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100